Mirum Pharmaceuticals (MIRM) Income towards Parent Company (2020 - 2025)
Historic Income towards Parent Company for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to $2.9 million.
- Mirum Pharmaceuticals' Income towards Parent Company rose 12040.74% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$41.4 million, marking a year-over-year increase of 5849.86%. This contributed to the annual value of -$87.9 million for FY2024, which is 4618.49% up from last year.
- As of Q3 2025, Mirum Pharmaceuticals' Income towards Parent Company stood at $2.9 million, which was up 12040.74% from -$5.9 million recorded in Q2 2025.
- In the past 5 years, Mirum Pharmaceuticals' Income towards Parent Company registered a high of $57.3 million during Q4 2021, and its lowest value of -$74.0 million during Q2 2023.
- Over the past 5 years, Mirum Pharmaceuticals' median Income towards Parent Company value was -$26.9 million (recorded in 2022), while the average stood at -$25.7 million.
- In the last 5 years, Mirum Pharmaceuticals' Income towards Parent Company surged by 25352.45% in 2021 and then tumbled by 17500.93% in 2023.
- Quarter analysis of 5 years shows Mirum Pharmaceuticals' Income towards Parent Company stood at $57.3 million in 2021, then tumbled by 163.6% to -$36.4 million in 2022, then increased by 2.12% to -$35.7 million in 2023, then skyrocketed by 33.28% to -$23.8 million in 2024, then skyrocketed by 112.21% to $2.9 million in 2025.
- Its Income towards Parent Company stands at $2.9 million for Q3 2025, versus -$5.9 million for Q2 2025 and -$14.7 million for Q1 2025.